Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.61), $0.08 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $16.26 million versus the consensus estimate of $8.54 million.

“We are very pleased to announce our first regulatory submission to initiate a Phase 1 study of NTLA-2001, which is an important milestone as we deliver on our mission to develop curative, CRISPR/Cas9-based treatments for severe diseases. Our CTA keeps us on track to dose our first ATTR patient by year-end and is a critical step in executing our global development strategy for the first systemically delivered CRISPR-based therapy to enter clinical trial,” said Intellia President and Chief Executive Officer, John Leonard, M.D. “With our recently expanded collaboration with Regeneron and subsequent financing, we are well-capitalized to advance our initial wave of development programs and continue our work developing innovative modular platform capabilities.”

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.